US5824331A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bioartificial devices and cellular matrices therefor
Assignee: Encelle Inc
•
Filing: 1995-12-07
•
Granted: 1998-10-20
•
Expires: 2015-12-07
Abstract
Abstract A device for the effective release of cellular moieties, including hormones, wherein a matrix containing a hormone producing cellular moiety is encapsulated with a nonimmunogenic polymeric material of poly-para-xylylene or other aromatic based polymeric moiety having a membrane portion with a porosity blocking passage therethrough of immunogenic agents and permitting passage therethrough of effective nutrients for said cellular moiety and the hormone produced thereby, an improved matrix for the storage, manufacture, functional testing, and viral infection testing of cellular moieties wherein a collagen based hydrogel is processed to present a liquid phase at host temperature and functions as a substrate for cellular attachment with additives effective for limiting thermal and pressure trauma, and an improved method for the harvesting tissue from organs.
Inventors
- 👤 Anton-Lewis Usala
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:07
CPC Classifications
A; A01; A01N; A01N1/00; A01N1/10; A01N1/12; A01N1/128; A61; A61F; A61F2/00; A61F2/02; A61F2/022; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61L; A61L27/00; A61L27/14; A61L27/22; A61L27/222; A61L27/24; A61L27/26; A61L27/36; A61L27/38; C; C12; C12N; C12N5/00; C12N5/0012; C12N5/06; C12N5/0602; C12N5/0676; C12N5/0677; A61F2310/00; A61F2310/00005; A61F2310/00365; A61K35/00; A61K35/12; A61K2035/126; A61K38/00; C12N2500/00; C12N2500/05; C12N2500/30; C12N2500/32; C12N2509/00; C12N2533/00; C12N2533/30; C12N2533/50; C12N2533/54; C12N2533/70
Claims Analysis
Total Claims: 55
Claim 1
Independent Claim
96 words
An improved storage matrix for prolonging the functional survival of cellular tissue, comprising: denatured collagen and intact collagen for providing binding sites for said tissue in an amount of about 0.01 to 30 mM; a liquid in a n amount of about 15 to 96.5 percent by weight; a polymeric buffer substrate for reducing cellular damage to said islets at said storage temperature in an amount of about 0.01 to 1000 micromolar, wherein said substrate forms a membrane coating having a porosity to permit passage of nutrients and biological agents and prevent passage of immunogenic agents.
Claim 2
Dependent Claim
96 words
An improved storage matrix for prolonging the functional survival of cellular tissue, comprising: denatured collagen and intact collagen for providing binding sites for said tissue in an amount of about 0.01 to 30 mM; a liquid in a n amount of about 15 to 96.5 percent by weight; a polymeric buffer substrate for reducing cellular damage to said islets at said storage temperature in an amount of about 0.01 to 1000 micromolar, wherein said substrate forms a membrane coating having a porosity to permit passage of nutrients and biological agents and prevent passage of immunogenic agents.
Claim 3
Dependent Claim
20 words
The matrix as recited in claim 1 wherein said polymeric buffer substrate is a long chain carbohydrate based polymer sugar.
Claim 4
Dependent Claim
14 words
The matrix as recited in claim 2 wherein said polymeric buffer substrate is dextran.
Claim 5
Dependent Claim
13 words
The matrix as recited in claim 1 wherein said polymeric substrate is amylopectin.
Claim 6
Dependent Claim
15 words
The matrix as recited in claim 1 wherein said polymeric substrate is a polymeric proteoglycan.
Claim 7
Dependent Claim
27 words
The matrix as recited in claim 1 wherein said nitric oxide inhibitor is a sulfanated moiety protecting protecting the tissue from hypoxic, chemical, thermal, or mechanical trauma.
Claim 8
Dependent Claim
23 words
The matrix as recited in claim 6 wherein said nitric oxide savenger is selected from the group comprising dextran, heparin, cysteine, and cystine.
Claim 9
Dependent Claim
16 words
The matrix as recited in claim 7 wherein said nitric oxide inhibitor is an L-arginine analog.
Claim 10
Dependent Claim
34 words
The matrix as recited in claim 8 wherein said l-arginine analog is selected from the group comprising aminoguanidine, N-monoethyl L-arginine, N-nitro-L-arginine, or D-arginine functioning to replace L-arginine as a substrate for nitric oxide formation.
Claim 11
Dependent Claim
50 words
A hydrogel matrix suitable for long term storage of cellular tissue comprising from about 15 to 96.5 percent by weight of an aqueous nutrient solution containing 0.001 to 100 mM collagen 0.01 to 1000 micromolar cryoprotectant 0.001 to 100 mM divalent chelator 0.01 micromolar to 300 mM nitric oxide inhibitor.
Claim 12
Dependent Claim
50 words
A hydrogel matrix suitable for long term storage of cellular tissue comprising from about 15 to 96.5 percent by weight of an aqueous nutrient solution containing 0.001 to 100 mM collagen 0.01 to 1000 micromolar cryoprotectant 0.001 to 100 mM divalent chelator 0.01 micromolar to 300 mM nitric oxide inhibitor.
Claim 13
Dependent Claim
12 words
The matrix of claim 10 wherein the collagen is a denatured collagen.
Claim 14
Dependent Claim
17 words
The matrix of claim 10 wherein the coliagen is a combination of denatured collagen and native collagen.
Claim 15
Dependent Claim
16 words
The matrix of claim 10 wherein the cryoprotectant i s a long chain carbohydrate based sugar.
Claim 16
Dependent Claim
21 words
The matrix of claim 10 wherein the cryoprotectant is selected from the group consisting of dextran, sulfated dextran, anylopectin and proteoglycan.
Claim 17
Dependent Claim
14 words
The matrix of claim 10 wherein the nitric oxide inhibitor is an amino acid.
Claim 18
Dependent Claim
22 words
The matrix of claim 10 wherein the nitric oxide inhibitor is selected from the group consisting of dextran, heparin, cysteine and cystine.
Claim 19
Dependent Claim
14 words
The matrix of claim 10 wherein the nitric oxide inhibitor is an L-arginine analog.
Claim 20
Dependent Claim
21 words
The matrix of claim 17 wherein said L-arginine analog is selected from the group consisting of aminoguanidine, N-monoethyl L-arginine and N-nitro-L-arginine.
Claim 21
Dependent Claim
20 words
The matrix of claim 10 wherein the divalent chelator is selected from the group consisting of citrate, EDTA and EGTA.
Claim 22
Dependent Claim
14 words
The matrix of claim 10 wherein the nutrient solution includes a water soluble protein.
Claim 23
Dependent Claim
9 words
The matrix of claim 10 additionally comprising an antibiotic.
Claim 24
Dependent Claim
23 words
The hydrogel matrix of claim 10 characterized in that said matrix is a solid at 4° C. and a liquid at 37° C.
Claim 25
Dependent Claim
49 words
A storage matrix for prolonging the functional survival of cellular tissue comprising collagen in an amount sufficient to provide a structural rigidity, water, and a polymeric buffer to provide a membrane coating having a porosity to permit passage of nutrients and biological agents and prevent passage of immunogenic agents.
Claim 26
Dependent Claim
49 words
A storage matrix for prolonging the functional survival of cellular tissue comprising collagen in an amount sufficient to provide a structural rigidity, water, and a polymeric buffer to provide a membrane coating having a porosity to permit passage of nutrients and biological agents and prevent passage of immunogenic agents.
Claim 27
Dependent Claim
12 words
The matrix of claim 23, wherein said collagen is a denatured collagen.
Claim 28
Dependent Claim
17 words
The matrix of claim 23, wherein said collagen is a combination of denatured collagen and native collagen.
Claim 29
Dependent Claim
10 words
The matrix of claim 23, further comprising a divalent chelator.
Claim 30
Dependent Claim
11 words
The matrix of claim 25, further comprising a nitric oxide inhibitor.
Claim 31
Dependent Claim
11 words
The matrix of claim 26, further comprising a nitric oxide inhibitor.
Claim 32
Dependent Claim
9 words
The matrix of claim 25, further comprising a cryoprotectant.
Claim 33
Dependent Claim
9 words
The matrix of claim 28, further comprising a cryoprotectant.
Claim 34
Dependent Claim
14 words
The matrix of claim 30, wherein said cryoprotectant is a long chain carbohydrate-based sugar.
Claim 35
Dependent Claim
21 words
The matrix of claim 31, wherein said cryoprotectant is selected from the group consisting of dextran, sulfated dextran, amylopectin and proteoglycan.
Claim 36
Dependent Claim
14 words
The matrix of claim 28, wherein said nitric oxide inhibitor is an amino acid.
Claim 37
Dependent Claim
22 words
The matrix of claim 28, wherein said nitric oxide inhibitor is selected from the group consisting of dextran, heparin, cysteine and cystine.
Claim 38
Dependent Claim
14 words
The matrix of claim 33, wherein said nitric oxide inhibitor is an L-arginine analog.
Claim 39
Dependent Claim
21 words
The matrix of claim 35, wherein said L-arginine analog is selected from thc group consisting of aminoguanidine, N-monoethyl L-arginine, and N-nitro-L-arginine.
Claim 40
Dependent Claim
20 words
The matrix of claim 26, wherein said divalent chelator is selected from the group consisting of citrate, EDTA, and EGTA.
Claim 41
Dependent Claim
9 words
The matrix of claim 23, further comprising an antibiotic.
Claim 42
Independent Claim
65 words
A method for prolonging the functional survival of cellular tissue, said method comprising placing said tissue in a storage matrix comprising a combination of denatured collagen and native collagen in an amount sufficient to provide a structural rigidity, and a polymeric buffer to provide a membrane coating having a porosity to permit passage of nutrients and biological agents and prevent the passage of immunogenic agents.
Claim 43
Independent Claim
65 words
A method for prolonging the functional survival of cellular tissue, said method comprising placing said tissue in a storage matrix comprising a combination of denatured collagen and native collagen in an amount sufficient to provide a structural rigidity, and a polymeric buffer to provide a membrane coating having a porosity to permit passage of nutrients and biological agents and prevent the passage of immunogenic agents.
Claim 44
Dependent Claim
13 words
The method of claim 39, wherein said matrix further comprises a divalent chelator.
Claim 45
Dependent Claim
14 words
The method of claim 40, wherein said matrix further comprises a nitric oxide inhibitor.
Claim 46
Dependent Claim
12 words
The method of claim 41, wherein said matrix further comprises a cryoprotectant.
Claim 47
Dependent Claim
12 words
The method of claim 40, wherein said matrix further comprises a cryoprotectant.
Claim 48
Dependent Claim
14 words
The method of claim 43, wherein said cryoprotectant is a long chain carbohydrate-based sugar.
Claim 49
Dependent Claim
21 words
The method of claim 43, wherein said cryoprotectant is selected from the group consisting of dextran, sulfated dextran, amylopectin and proteoglycan.
Claim 50
Dependent Claim
14 words
The method of claim 41, wherein said nitric oxide inhibitor is an amino acid.
Claim 51
Dependent Claim
22 words
The method of claim 41, wherein said nitric oxide inhibitor is selected from the group consisting of dextran, heparin, cysteine and cystine.
Claim 52
Dependent Claim
14 words
The method of claim 46, wherein said nitric oxide inhibitor is an L-arginine analog.
Claim 53
Dependent Claim
21 words
The method of claim 48, wherein said L-arginine analog is selected from the group consisting of aminoguanidine, N-monoethyl L-arginine, and N-nitro-L-arginine.
Claim 54
Dependent Claim
20 words
The method of claim 40, wherein said divalent chelator is selected from the group consisting of citrate, EDTA, and EGTA.
Claim 55
Dependent Claim
12 words
The method of claim 39, wherein said matrix further comprises an antibiotic.
References Cited (Backward Citations)
US4868121A
Cited
US5322790A
Cited
US4696286A
Cited
US4797213A
Cited
US5079160A
Cited
WO1992019195A1
Cited
WO1993016685A1
Cited
WO1995019430A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-10-19 | 2002-04-20 | 2002-10-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-10-19 | 2006-04-20 | 2006-10-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-10-19 | 2010-04-20 | 2010-10-20 | $7700.00 | Window Closed / Lapsed |